Rebranding, a $545M private placement, and a pivot to a digital asset treasury? This is a full-blown metamorphosis. 🐛 The stock is digesting it all, trading below both key WMAs with an RSI in the "meh" low-40s. No panic selling, just cautious drift. This is a bet on the new Canton strategy, not the old biotech. High-risk, high-reward. If you believe in the pivot, this weakness is a speculative BUY. If not, stay far away. #AsymmetricBet

FDA's blessing on their fentanyl-blocker is HUGE news, and the market's starting to wake up. 📈 The stock got way oversold (RSI in the 30s!), but check the bounce today—closing near the high on decent volume. This looks like the start of a real reversal. With that $545M war chest and a national security angle, I'm calling this a BUY. #RocketFuel

This biotech is buzzing! 🐝 Major patents, FDA nods, and a weaponized fentanyl solution – that's rocket fuel. The stock is shaking off its October 10th plunge, with the 9-day EMA sneaking above the 21-day. RSI is neutral, so there's room to run. With news this potent and the chart finding its legs, I'm calling this a speculative BUY. #BioBounce

Whoa, Tharimmune just dropped a bomb with that national security patent news! 🚀 The stock exploded from $1.17 to $2.38 on absolutely massive volume—we're talking 243 million shares! The RSI is hot at 75, so it's overbought and due for a breather. But this kind of volume on game-changing news is a powerful signal. This isn't retail chatter; it's a potential paradigm shift. BUY the dip. #FentanylFighter